Search results
Nov 10, 2021 · We conducted the Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after Myocardial Infarction (PARADISE-MI), an international, multicenter ...
- Marc A. Pfeffer, Brian Claggett, Eldrin F. Lewis, Christopher B. Granger, Lars Køber, Aldo P. Maggio...
- 2021
Jun 26, 2019 · ARNI improved functional capacity in patients with heart failure (HF) and a reduced ejection fraction (EF), including increasing New York Heart Association functional class (MD −0.79, 95% CI −0.86, −0.71) and 6‐minute walking distance (MD 27.62 m, 95% CI 15.76, 39.48).
- Yiwen Wang, Ran Zhou, Chi Lu, Qing Chen, Tongda Xu, Dongye Li
- 2019
Angiotensin Receptor–Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction. Mark H. Drazner, MD, MSc 1. Author Affiliations Article Information. 1 Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
- Mark H. Drazner
- 2019
Mar 8, 2024 · Contemporary use of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and angiotensin receptor‐neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF) has not been described.
Apr 17, 2023 · ARNI has demonstrated superior cardioprotective effects compared with renin–angiotensin system inhibitors (RAS‐Is) in large clinical trials such as the PARADIGM‐HF (Prospective Comparison of ARNI With ACEI [Angiotensin‐Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial.
May 2, 2022 · This review focuses on the potential utilization of angiotensin receptor–neprilysin inhibitors (ARNIs) to manage conditions in the continuum from hypertension to heart failure based on...
People also ask
What does Arni stand for?
Is Arni a renin-angiotensin system inhibitor?
Does Arni improve functional capacity in patients with heart failure?
Can Arni treat cardiac hypertrophy?
Jul 21, 2021 · Angiotensin receptor-neprilysin inhibitors (ARNIs) are a new class of cardiovascular agents characterized by their dual action on the major regulators of the cardiovascular system,...
